Dr. Karagiannidis is the Chief Scientific Officer in Athos Therapeutics Inc. Currently, he organizes and oversees all the in vitro and in vivo preclinical drug discovery & development studies. He has an extensive experience studying the pathobiology of Inflammatory Bowel Diseases and working with different IBD mouse models. He received his Ph.D from Boston University School of Medicine, where he studied the effects of transcription factor regulation of aging processes in adipose tissue stem cell populations. He completed his post-doctoral training at Beth Israel Deaconess Medical Center at Harvard medical school in Dr. Charalabos Pothoulakis laboratory. During his tenure as a faculty at UCLA David Geffen School of Medicine, he led several projects in his capacity as Director of the Immune Assays Core and Associate Director of the Center for Systems Biomedicine, participating in the discovery and development of drugs that targeted epigenetic mechanisms in IBD. He has more than 40 scientific publications in top biomedical journals and he is a member of the American Gastroenterology Association.
